ENG and ovarian cancer: The downregulation of CD105 expression with a clinically relevant CD105-neutralizing mAb (TRC105) inhibited high-grade serous cancer metastasis, reduced ascites, and hampered the growth of abdominal tumor nodules in animal models of ovarian cancer [39].